Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study by Ravassa, Susana et al.
International Journal of Cardiology 185 (2015) 177–185
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rdBiomarkers of cardiomyocyte injury and stress identify left atrial and left
ventricular remodelling and dysfunction: A population-based studySusana Ravassa a,1, Tatiana Kuznetsova b,1, Nerea Varo c, Lutgarde Thijs b, Christian Delles d, Anna Dominiczak d,
Javier Díez a,e,⁎, Jan A. Staessen b,f,⁎⁎
a Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain
b The Studies Coordinating Centre, Research Unit of Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium
c Department of Biochemistry, University of Navarra Clinic, University of Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona Spain
d Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, UK
e Department of Cardiology and Cardiac Surgery, University of Navarra Clinic, University of Navarra, IdiSNA-Navarra Institute for Health Research, Pamplona, Spain
f Department of Epidemiology, University of Maastricht, Maastricht, The NetherlandsAbbreviations:A, peak late diastolic velocity, transmitr
annular velocity; EF, ejection fraction; hs-cTnT, high sensi
left atrial volume index; LV, left ventricular; LVDD, left ven
ventricular hypertrophy;NRI, net reclassification improve
aminoterminal propeptide of procollagen type III; TDI, tissu
⁎ Correspondence to: J. Díez, Program of Cardiovascula
⁎⁎ Correspondence to: J.A. Staessen, Research Unit of Hy
Sint Rafaël, Kapucijnenvoer 35, Block D, Box 7001, B 3000
E-mail addresses: jadimar@unav.es (J. Díez), jan.staess
1 Both authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ijcard.2015.03.046
0167-5273/© 2015 Elsevier Ireland Ltd. All rights reserveda b s t r a c ta r t i c l e i n f oArticle history:
Received 18 March 2014
Received in revised form 22 December 2014
Accepted 3 March 2015
Available online 4 March 2015
Keywords:
hs-cTnT
Left ventricular remodelling
Left atrial remodelling
Diastolic dysfunction
Collagen metabolism
NT-proBNP
Background/objectives: The validation of effective screening tools for the identification of patientswith subclinical
myocardial remodelling is a major clinical need. Thus, we explored the associations of circulating biomarkers of
cardiomyocyte injury and stress with subclinical cardiac remodelling and dysfunction, and with biomarkers
reflecting collagen turnover.
Methods:We randomly recruited 727 subjects from a general population (51.2% women; mean age 51.3 years).
Measurements included echocardiographic left atrial (LA) and left ventricular (LV) structure and function, quan-
tification of high sensitivity cardiac Troponin T (hs-cTnT), NT-proBNP, and biomarkers of collagen types I and III
turnover.
Results: In unadjusted and adjusted analyses, the prevalence of LA enlargement (LAE), LV hypertrophy (LVH) and
LV diastolic dysfunction (LVDD) increasedwith higher hs-cTnT (P≤ 0.031). NT-proBNPwas independently asso-
ciated with LVDD (P= 0.009). Both biomarkers combined yielded significant integrated discrimination and net
reclassification improvements (P ≤ 0.014 and P ≤ 0.009, respectively) for LAE, LVH and LVDD, over the conven-
tional risk factors, andwere independently and positively associatedwith biomarkers of collagen type I turnover.
In a sensitivity analysis, after excluding participants with previous cardiac diseases, our findings remained
consistent.
Conclusions: Our population-based study suggested that subclinical LV and LA remodelling were associated
with hs-cTnT, and that, in combination with NT-proBNP, hs-cTnT showed incremental diagnostic utility
over the conventional risk factors. Both biomarkers were associated with biomarkers of collagen type I
turnover. Thus, biomarkers of cardiomyocyte microinjury and hemodynamic stress may stimulate
fibrosis-related mechanisms and facilitate the diagnosis of subclinical LA and LV remodelling and dysfunc-
tion in the general population.© 2015 Elsevier Ireland Ltd. All rights reserved.al; CITP, carboxyterminal telopeptide of type I collagen; E, peak early diastolic velocity, transmitral; e′, peak early diastolicmitral
tivity cardiac Troponin T; HF, heart failure; IVRT, isovolumetric relaxation time; LA, left atrial; LAE, left atrial enlargement; LAVI,
tricular diastolic dysfunction; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; LVH, left
ment; NT-proBNP, amino-terminal pro-brain natriuretic peptide; PICP, carboxyterminal propeptide of procollagen type I; PIIINP,
eDoppler imaging; TIMP-1, tissue inhibitor of thematrixmetalloproteinase type 1.
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Heart failure (HF) is a progressive condition that begins with risk
factors (e.g., hypertension), proceeds to cardiac remodelling (e.g., left
ventricular (LV) hypertrophy and left atrial enlargement) and changes
in LV function (e.g., diastolic and systolic dysfunction), and then evolves
into clinically overt HF, disability and death [1]. The validation of effec-
tive screening tools for the identification of patients at the early stage of
LV remodelling (diagnostic markers) is a major clinical need.
The cardiac troponin complex includes troponin T (cTnT) protein
which is tightly bound to the cardiac tropomyosin complex [2]. The
mechanisms underlying cTnT release from cardiomyocytesmight be re-
lated to myocyte necrosis and apoptosis, to increased cardiomyocyte
wall permeability, or to normal cardiomyocyte turnover [3]. Patients
with symptomatic HF outside the context of clinically apparent ische-
mia (myocardial infarction) have increased levels of circulating cTnT
detected with a high sensitivity assay (hs-cTnT) [2]. In the general pop-
ulation, LV hypertrophy (LVH) is associated with elevated hs-cTnT
levels [4,5]. Independently of other cardiovascular risk factors, hs-cTnT
levels predict incident HF [6] and total mortality [4,6].
Brain natriuretic peptide (BNP) is released from cardiomyocytes in re-
sponse to an increase of atrial or ventricular diastolic stretch to stimulate
natriuresis and vasodilatation and to facilitate LV relaxation [7]. Secreted
pro-BNP is subsequently cleaved in the blood into amino terminal-pro-
BNP (NT-proBNP) and BNP. NT-proBNP values vary with the degree of
LV diastolic dysfunction (LVDD) [8]. Moreover, in combination with hs-
cTnT, NT-proBNP identifies a malignant phenotype of LVH with high
risk for HF and cardiovascular death in the general population [9].
Cardiomyocytemicroinjurymay be associatedwith dysregulation of
the collagen deposition process in elderly patients with HF [10]. Indeed,
biological processes related to cardiomyocyte microinjury can activate
collagen turnover and, therefore, lead to myocardial fibrosis even in
the absence of myocardial infarction [11]. Biomarkers of collagen
metabolism relevant to myocardial fibrosis include, among others,
carboxyterminal propeptide of procollagen type I (PICP), a marker
of type I collagen synthesis; carboxyterminal telopeptide of type I
collagen (CITP) and tissue inhibitor of the matrix metalloprotein-
ase type 1 (TIMP-1) as markers of degradation of type I collagen;
and aminoterminal propeptide of procollagen type III (PIIINP), a
marker of synthesis and degradation of type III collagen [12].
The objective of our study was to gain further insight into the asso-
ciation of subclinical myocardial remodelling, considering not only LV
but also left atrial (LA) morphology, with circulating biomarkers of car-
diomyocyte injury (hs-cTnT) and cardiomyocyte stress (NT-proBNP). In
addition, we also explored the associations of hs-cTnT and NT-proBNP
with biomarkers reflecting collagen turnover. All these aspects were in-
vestigated in subjects randomly selected from a Flemish population.
2. Methods
2.1. Study participants
The Ethics Committee of the University of Leuven approved the Flem-
ish Study on Environment, Genes and Health Outcomes (FLEMENGHO).
Detailed explanation of the studyparticipants is provided in theData Sup-
plement. Briefly, fromMay 2005 until May 2010, we invited 1208 former
participants from a previously identified random population for a follow-
up examination at thefield centre, including echocardiography. However,
153 participants were unavailable for follow-up, because they had died
(n = 26), because they had been institutionalised or were too ill (n =
27), or because they hadmoved out of the area (n=100). Of the remain-
ing 1055 former participants, 828 renewed their informed consent. The
participation rate for the follow-up examination was therefore 78.5%.
We excluded 15 subjects, because of atrialfibrillation (n=8) or the pres-
ence of an artificial pacemaker (n = 3), or because diastolic function
could not be reliably determined (n = 4). We discarded further 86subjects from analysis because serum samples were not available (n =
44) or the amount of serum was insufficient (n = 42) for hs-cTnT mea-
surements. Therefore, the number of participants statistically analysed to-
taled 727.
2.2. Echocardiography
The participants refrained from smoking, heavy exercise, and drinking
alcohol or caffeine-containing beverages for at least 3 h before echocardi-
ography. The blood pressure during echocardiographywas the average of
two readings, obtained with a validated OMRON 705IT device (Omron
Corp., Tokyo, Japan) at the end of the echocardiographic examination.
A complete echocardiographic protocol and reproducibility study
are provided in theData Supplement. Briefly, one experienced physician
(T.K.) did the ultrasound examination [8], using a Vivid7 Pro (GE
Vingmed, Horten, Norway) interfaced with a 2.5- to 3.5-MHz phased-
array probe, according to the recommendations of the American Society
of Echocardiography [13]. All digitally stored images were analysed,
averaging 3 heart cycles for statistical analysis, using a workstation run-
ning the EchoPac, version 4.0.4 software package (GE Vingmed, Horten,
Norway). End-diastolic LV dimensions were used to calculate LV
mass by an anatomically validated formula. LV mass index (LVMI)
was LV mass divided by body surface area (BSA). LVH was a LV
mass index exceeding 110 g/m2 in women, and 125 g/m2 in men
[14]. We measured LA dimensions in 3 orthogonal planes: the
parasternal long, lateral, and supero-inferior axes. LA volume was
calculated using the prolate-ellipsoid method and was indexed to
BSA. LA enlargement (LAE) was a LA volume index (LAVI) exceeding
29 ml/m2 [15].
From the transmitral flow signal, we measured peak early diastolic
velocity (E), peak late diastolic velocity (A), the E/A ratio, andA flowdu-
ration. From the PVflow signal,wemeasured theduration of PV reversal
time during atrial systole (AR). From the TDI recordings, we measured
peak early (e′) diastolic mitral annular velocity at the 4 acquisition
sites (septal, lateral, inferior, and posterior).We combined themitral in-
flow and TDI velocities to classify the stages of LVDD at baseline as pre-
viously described [8,16]. The first group included subjects with an
abnormally low age-specific transmitral E/A ratio indicative of impaired
relaxation, but without evidence of increased LV filling pressures
(E/e′ ≤ 8.5). The second group had mildly-to-moderately elevated
LV filling pressures (E/e′ N 8.5), and E/A ratio within the normal
age-specific range. We also used the differences in durations be-
tween themitral A flow and the reverse PV flow during atrial systole
(Ad b ARd + 10) and/or LAVI (N29 ml/m2) to confirm possible
elevation of the LV filling pressures in group 2. Group 3 had an ele-
vated E/e′ ratio and an abnormally low age-specific E/A ratio (com-
bined dysfunction). Of notice, the prognostic significance of the
considered LVDD classification in the current study has been proven
in the general population [17].
2.3. Biochemical measurements
A complete description of the biochemical measurements is provided
in the Data Supplement. Briefly, hs-cTnT levels were measured in serum
using a highly sensitive assay (Troponin Ths STAT, RocheDiagnostics) op-
timized on the Cobas 8000 modular analyser series (Roche Diagnostics).
PICP was quantified in serum by sandwich enzyme linked immunosor-
bent assay (ELISA) using the METRA EIA kit (Quidel Corporation, San
Diego, CA), serum CITPwas determined by a quantitative enzyme immu-
noassay (EIA) (OrionDiagnostica, Espoo, Finland), free TIMP-1was deter-
mined in serum by the ELISA method (TIMP-1 Human Biotrak ELISA
System from GE Healthcare, UK Limited) and PIIINP was assessed in
serum as a marker of collagen type III turnover by ELISA (MyBioSource,
San Diago, CA). NT-proBNP was measured in plasma by a competitive
EIA for research use (Biomedica Gruppe, Vienna, Austria). From the con-
sidered 727 participants, plasma samples from 33 subjects were not
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2.4. Statistical methods
For database management and statistical analysis, we used SAS soft-
ware, version 9.3 (SAS Institute, Cary, NC). We normalized the distribu-
tions of all analysed biomarkers by a logarithmic transformation. We
compared means and proportions by means of a large sample z-test
and the χ2 statistics, respectively. Statistical significance was a 2-sided
significance level of 0.05. Our statistical methods included multiple lin-
ear and logistic regression analyses. We adjusted our models for
covariables with known physiological relevance for LA and LVmorphol-
ogy and LV diastolic function [8,18]. Calibration of the logistic models
was assessed using the Hosmer–Lemeshow goodness-of-fit statistic
with categories formed by deciles of risk. We compute multivariable-
adjusted effect sizes associated with a doubling of hs-cTnT and NT-
proBNP. Adjusted analyses of variance were used to compared bio-
markers of collagen turnover among hs-cTnT and NT-proBNP quartiles.
We calculated the integrated discrimination improvement (IDI) and
the continuous net reclassification index (NRI) as described by Pencina
et al. [19]. We predicted in each subject the risk for subclinical cardiac
remodelling or dysfunction from a logistic model with and without
biomarkers included. Let P (up/case) the percentage of cases whose pre-
dicted probability is increased by adding the biomarkers to the model
and P (up/noncase) the percentage of subjectswithout eventswhose pre-
dicted probability is increased. The NRI was then calculated as 2 ∗ [P (up/
case)− P (up/noncase)] [19]. The IDI is the difference between the dis-
crimination slopes of basicmodels and basicmodels extendedwith a pre-
dictor variable (biomarker). The discrimination slope is the difference in
predicted probabilities (%) between subjects with and without LAE, LVH
or LVDD.
3. Results
3.1. Characteristics of participants and distribution of biomarkers
The 727 participants included 372 (51.2%) women, and 299 (41.1%)
hypertensive patients, of whom 184 (25.3%) were on antihypertensive
drug treatment. The hs-cTnT concentration was below the limit of
blank (3 ng/l) in 46 (6.3%) subjects. The distribution of serum hs-cTnT
in those participants with the presence of the biomarker in the blood
(hs-cTnT N 3 ng/l, n= 681) departed from normality andwas positively
skewed (P b 0.0001) with a coefficient of skewness amounting to 2.43.
The geometric mean of serum hs-cTnT was 6 ng/l (interquartile range,
4.9–8.0 ng/l). Table 1 shows the clinical characteristics of the study par-
ticipants for the entire cohort and by quartiles of serum hs-cTnT and of
the participants with levels of hs-cTnT below the limit of blank (3 ng/l).
With higher serum hs-cTnT, there was an increase in age, body mass
index, systolic and diastolic blood pressure and heart rate (P b 0.0001,
Table 1). The prevalence ofmale sex and participantswith hypertension
and treated with antihypertensive drugs also increased with higher hs-
cTnT (P b 0.0001, Table 1). As expected, previous history of cardiac dis-
orders was more prevalent in subjects with higher hs-cTnT (P b 0.0001,
Table 1). In addition, NT-proBNP values were higher in subjects with
high levels of hs-cTnT (P= 0.030, Table 1).
The distribution of plasma NT-proBNP departed from normality and
was positively skewed (coefficient of skewness = 5.81, P b 0.0001). The
geometric mean of plasma NT-proBNP was 1745 ng/l (interquartile
range, 1203–2494 ng/l). Supplemental table S1 shows the clinical charac-
teristics of the participants by quartiles of NT-proBNP. Similar to what
weobserved for hs-cTnT, therewas an increase in age (Pb 0.0001), systol-
ic (P = 0.026) and diastolic (P= 0.003) blood pressure and heart rate
(P= 0.004) with higher plasma NT-proBNP (Supplemental table S1). Hy-
pertension and previous history of cardiac disorders were also more fre-
quently reported in subjects with higher NT-proBNP (Supplemental tableS1). The prevalence of male sex decreased with higher NT-proBNP
(P b 0.0001).
3.2. Associations between biomarkers of cardiomyocyte injury/stress and
continuous echocardiographic traits
Table 2 and Supplemental Table S2 show the echocardiographic data
in thewhole study population and grouped according to serum hs-cTnT
and plasma NT-proBNP quartiles, respectively. Total prevalence of LAE,
LVH and LVDD were 16.6%, 11.1% and 25.4%, respectively, in all partici-
pants. In unadjusted analyses in which we treated serum hs-cTnT as a
categorical variable (Table 2), LAVI, LV internal diastolic diameter, inter-
ventricular septum, posterior wall thickness, relative wall thickness and
LVMI increased with hs-cTnT (P b 0.0001 for all). In addition, Table 2
shows a decrease in transmitral E wave, an increase in transmitral A
wave, and subsequently a decrease of the E/A ratio with hs-cTnT
(P b 0.0001 for all). Furthermore, we also observed that TDI e′mitral an-
nulus velocity decreased and the E/e′ ratio increased with increasing
serum hs-cTnT (P b 0.0001). There were no significant differences
among the hs-cTnT quartiles in ejection fraction (EF) (Table 2).
In unadjusted analyses in whichwe treated the plasma NT-proBNP as
a categorical variable (Supplemental table S2), only LAVI (P b 0.0001) and
LVMI (P= 0.030) increased with plasma NT-proBNP. Furthermore, we
also observed a decrease in transmitral E/A ratio (P= 0.001) and TDI e′
mitral annulus velocity (P = 0.002) and an increase in transmitral A
wave (P b 0.0001), IVRT (P b 0.0001), deceleration time (P = 0.030)
and E/e′ ratio (P b 0.0001) with increasing quartiles of NT-proBNP
(Supplemental table S2).
In multivariable-adjusted analysis accounting for sex, age, body
mass index, systolic blood pressure, heart rate, serumcreatinine, history
of cardiac diseases and use of antihypertensive drugs, log-transformed
hs-cTnT was treated as a continuous variable. In these analyses, we in-
cluded subjects without the presence of circulating hs-cTnT by setting
hs-cTnT levels to the limit of blank (3 ng/l). Only LAVI (P b 0.0001), LV
internal diastolic diameter (P = 0.026) and LVMI (P = 0.009) signifi-
cantly increased with hs-cTnT in the multivariable-adjusted analyses
(Table 3). These observationswere further validated in a complementa-
ry analysis including subjects with hs-cTnT below the detection limit
(5 ng/l) by setting hs-cTnT levels to 4.9 ng/l (data not shown). In addi-
tion, log-transformed NT-proBNP was independently and directly asso-
ciated with LV internal diastolic diameter, LVEDV index, TDI e′ mitral
annulus velocity and IVRT (P b 0.05, Table 3).
3.3. Associations between biomarkers of cardiomyocyte injury/stress and
cardiac remodelling and LV diastolic dysfunction
Overall, in unadjusted analysis, the prevalence of LAE, LVH and LVDD
progressively increased with higher hs-cTnT and NT-proBNP (Fig. 1).
Table 4 shows the odds ratios of having LAE, LVH and LVDD associated
with serumhs-cTnT and plasmaNT-proBNP, adjusted for the important
covariables. In these analyses we also included subjects with hs-cTnT
levels below the limit of blank. A doubling of hs-cTnT was associated
with a 86% higher odds of LAE (P = 0.004), a 98% higher odds of LVH
(P=0.003), and a 56% higher odds of LVDD (P=0.031). The prevalence
of LVDD also increased with higher NT-proBNP (P= 0.009; Table 4).
The Hosmer–Lemeshow goodness-of-fit statistics for the models in-
cluding the traditional risk factors only were ≤5.14 (P≥ 0.74) suggest-
ing adequate fit. For LAE, LVH and LVDD, IDI reached significance
(P≤ 0.035) by adding hs-cTnT to themodel (Table 5). In addition, a sig-
nificant IDI was found for NT-proBNP and LVDD (P=0.039). According
to the NRI, the ability of the logistic model to discriminate between
subjects with and without LVH improved by adding hs-cTnT to a
model already including the conventional risk factors (38.6%, P =
0.001) (Table 5). Similarly, the continuous NRI obtained by adding NT-
proBNP to the conventional risk factors model was significant for LAE
(27.4%, P = 0.009) and LVDD (27.3%, P = 0.002). Adding both
Table 1
Clinical characteristics in all participants and by hs-cTnT quartiles.
Characteristic All participants
(n = 727)
hs-cTnT below the LoB
(n = 46)
hs-cTnT quartiles P-value
Low
(n = 149)
Medium-low
(n = 225)
Medium-high
(n = 145)
High
(n = 162)
Limits, ng/l b3.0 3.0–4.9 5.0–5.9 6.0–8.0 N8.0 –
Anthropometrics
Age, year 51.3 ± 15.4 36.7 ± 10.3 42.7 ± 12.9 50.2 ± 13.3 52.3 ± 13.9 63.9 ± 13.2 b .0001
Body mass index, kg/m2 26.4 ± 4.3 25.6 ± 4.9 24.9 ± 4.3 26.3 ± 4.0 27.0 ± 4.1 27.8 ± 4.1 b .0001
Sex, women n (%) 372 (51.2) 37 (80.4) 109 (73.2) 117 (52.0) 50 (34.5) 59 (36.4) b .0001
Systolic pressure, mm Hg 129.4 ± 17.6 117.8 ± 12.8 122.6 ± 15.1 128.2 ± 14.9 130.2 ± 16.9 139.9 ± 19.6 b .0001
Diastolic pressure, mm Hg 79.6 ± 9.4 75.4 ± 9.1 78.3 ± 9.8 79.9 ± 9.1 80.3 ± 8.9 80.7 ± 9.5 0.0006
Heart rate, beats/min 60.8 ± 9.7 63.8 ± 9.3 62.8 ± 9.1 61.1 ± 9.9 59.7 ± 9.8 58.8 ± 9.4 b .0001
Questionnaire data
Current smoking, n (%) 158 (21.7) 11 (23.9) 32 (21.5) 55 (24.4) 34 (23.4) 26 (16.0) 0.19
Drinking alcohol, n (%) 298 (41.0) 18 (39.1) 56 (37.6) 93 (41.3) 74 (51.0) 57 (35.2) 0.87
Hypertensive, n (%) 299 (41.1) 6 (13.0) 32 (21.5) 85 (37.8) 67 (46.2) 109 (67.3) b .0001
Treated for hypertension, n (%) 184 (25.3) 2 (4.3) 17 (11.4) 47 (20.9) 45 (31.0) 73 (45.1) b .0001
History of cardiac disorders,
n (%)
28 (3.9) 0 (0.0) 1 (0.7) 4 (1.8) 5 (3.4) 18 (11.2) b .0001
Biochemical data
Total cholesterol, mmol/l 5.27 ± 0.98 5.04 ± 1.06 5.18 ± 1.00 5.27 ± 0.94 5.30 ± 0.93 5.39 ± 1.01 0.015
Glucose, mmol/l 4.95 ± 0.81 4.70 ± 0.42 4.76 ± 0.42 4.90 ± 0.90 5.02 ± 0.64 5.19 ± 1.08 b .0001
Serum creatinine, mmol/l 84.4 ± 15.7 77.0 ± 11.0 79.0 ± 11.5 82.6 ± 13.0 89.9 ± 15.9 89.0 ± 20.0 b .0001
NT-proBNP, ng/l 1745 (803 to 3617) 1791 (700 to 4538) 1647 (889 to 3021) 1696 (767 to 3507) 1660 (735 to 3715) 1995 (903 to 4372) 0.030
PICP, μg/l 92.5 (59.5 to 156) 89.8 (59.4 to 155) 91.6 (59.5 to 162) 88.6 (60.5 to 153) 92.1 (60.0 to 160) 86.6 (58.4 to 148) 0.45
CITP, μg/l 5.24 (3.33 to 8.07) 5.74 (3.48 to 8.03) 5.08 (3.28 to 7.91) 5.03 (3.14 to 7.42) 5.20 (3.61 to 8.12) 5.83 (3.60 to 9.01) 0.002
PIIINP, μg/l 541 (243 to 1317) 586 (222 to 1205) 544 (260 to 1278) 535 (241 to 1281) 541 (257 to 1246) 525 (229 to 1559) 0.25
TIMP-1, μg/l 647 (478 to 887) 569 (432 to 745) 615 (433 to 838) 626 (485 to 845) 642 (483 to 876) 723 (526 to 994) b .0001
Values are mean (±SD), geometric mean (10% to 90% interval), or number of subjects (%). hs-cTnT indicates hs-cardiac troponin T; LoB, limit of blank; NT-proBNP, amino terminal-pro-
BNP; PICP, carboxyterminal propeptide of procollagen type I; CITP, carboxyterminal telopeptide of type I collagen; PIIINP, amino terminal propeptide of procollagen type III; TIMP-1, tissue
inhibitor of the matrix metalloproteinase type 1. P-values are for differences across groups.
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27.7% (P = 0.008) for LAE, 32.8% (P = 0.009) for LVH and 29.3% (P =
0.0007) for LVDD (Table 5).
3.4. Associations between biomarkers of cardiomyocyte injury/stress and
collagen turnover
In unadjusted analysis, both biomarkers of collagen type I turnover,
CITP (P = 0.002) and TIMP-1 (P b 0.0001), increased with increasing
hs-cTnT quartiles (Table 1). No associations were found between hs-
cTnT and PICP or PIIINP. Similarly, we observed progressively higherTable 2
Echocardiographic characteristics of participants by hs-cTnT quartiles.
Characteristic All participants
(n = 727)
hs-cTnT below the LoB
(n = 46)
Limits, ng/l b3.0
Conventional echocardiography
Left atrial volume index, ml/m2 23.0 ± 6.3 20.0 ± 4.5
LV internal diastolic diameter, mm 50.5 ± 4.8 49.6 ± 3.7
LVEDV index, ml/m2 53.4 ± 11.2 53.2 ± 9.2
LVESV index, ml/m2 20.2 ± 5.7 19.8 ± 4.4
Interventricular septum, mm 9.8 ± 1.7 8.8 ± 1.3
Posterior wall, mm 9.0 ± 1.5 8.2 ± 1.2
Relative wall thickness 0.37 ± 0.07 0.35 ± 0.05
LV mass, g 173.2 ± 49.4 147.4 ± 35.2
LV mass index, g/m2 92.8 ± 22.2 80.8 ± 18.4
Ejection fraction, % 63.1 ± 6.8 63.9 ± 6.2
Doppler echocardiography
Transmitral E wave, cm/s 75.4 ± 16.0 84.5 ± 13.5
Transmitral A wave, cm/s 65.2 ± 17.6 55.6 ± 10.6
Transmitral E/A ratio 1.26 ± 0.48 1.56 ± 0.34
IVRT, ms 98.5 ± 15.8 91.0 ± 14.6
Deceleration time, ms 167.9 ± 37.1 147.5 ± 21.4
e′, cm/s 11.4 ± 3.6 14.4 ± 2.9
E/e′ ratio 7.1 ± 2.1 6.0 ± 1.1
Values aremean± SD. hs-cTnT indicates hs-cardiac troponin T; LoB, limit of blank; LV, left vent
ume; IVRT, isovolumic relaxation time. P-values are for differences across groups.values of CITP (P= 0.001) and TIMP-1 (P b 0.0001) with increasing NT-
proBNP quartiles, whereas there were no significant differences among
the NT-proBNP quartiles in PICP and PIIINP (Supplemental Table S1). In
the multivariable-adjusted regression analysis in which we treated the
log-transformed biomarkers as continuous variables and included sub-
jects with hs-cTnT levels below the limit of blank, hs-cTnT was indepen-
dently and curvilinearly associated with CITP (P= 0.008; Fig. 2A). This
relationship was modelled using the quadratic term of hs-cTnT. In addi-
tion, multivariate regression analysis including the quadratic term of hs-
cTnT showed the association between hs-cTnT and TIMP-1 (P= 0.010;
Fig. 2B) independently of relevant confounding factors. Similarly, NT-hs-cTnT quartiles P-value
Low
(n = 149)
Medium-low
(n = 225)
Medium-high
(n = 145)
High
(n = 162)
3.0–4.9 5.0–5.9 6.0–8.0 N8.0 –
19.5 ± 4.2 22.2 ± 5.4 24.3 ± 6.2 26.9 ± 7.2 b .0001
48.9 ± 4.4 50.3 ± 4.6 51.1 ± 4.7 51.8 ± 5.4 b .0001
49.9 ± 8.9 53.3 ± 10.8 56.6 ± 12.1 54.3 ± 12.5 0.001
18.9 ± 4.7 20.2 ± 5.5 21.6 ± 6.0 20.4 ± 6.6 0.014
9.1 ± 1.4 9.6 ± 1.5 10.3 ± 1.6 10.7 ± 1.7 b .0001
8.3 ± 1.3 8.7 ± 1.4 9.4 ± 1.4 9.8 ± 1.4 b .0001
0.36 ± 0.06 0.36 ± 0.06 0.39 ± 0.07 0.40 ± 0.07 b .0001
146.8 ± 36.5 166.2 ± 45.6 187.5 ± 46.1 201.5 ± 52.3 b .0001
81.3 ± 14.7 88.9 ± 19.6 98.0 ± 19.5 107.6 ± 25.0 b .0001
62.9 ± 6.3 63.2 ± 6.8 62.7 ± 6.1 63.3 ± 7.8 0.82
80.4 ± 14.5 75.7 ± 16.0 72.8 ± 16.0 70.0 ± 15.6 b .0001
59.0 ± 14.8 65.1 ± 17.8 64.8 ± 17.7 73.9 ± 17.2 b .0001
1.45 ± 0.45 1.26 ± 0.48 1.23 ± 0.52 1.00 ± 0.34 b .0001
93.7 ± 14.2 98.5 ± 14.4 98.8 ± 15.6 105.2 ± 17.2 b .0001
156.3 ± 25.4 167.1 ± 32.6 169.6 ± 34.5 184.1 ± 49.2 b .0001
13.3 ± 3.2 11.6 ± 3.6 10.8 ± 3.3 9.0 ± 2.7 b .0001
6.3 ± 1.5 7.0 ± 2.1 7.2 ± 2.1 8.2 ± 2.5 b .0001
ricle; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic vol-
Table 3
Adjusted echocardiographic traits in relation to hs-cTnT and NT-proBNP.
Characteristics Serum hs-cTnT (n = 727) Plasma NT-proBNP (n = 694)
Estimate 95% CI P Estimate 95% CI P
Left atrial volume index, ml/m2 1.39 0.65 to 2.13 b .0001 0.38 −0.10 to 0.86 0.12
LV morphology
LV internal diastolic diameter, mm 0.64 0.075 to 1.21 0.026 0.57 0.20 to 0.94 0.003
LVEDV index, ml/m2 0.82 −0.64 to 2.29 0.27 1.58 0.65 to 2.52 0.001
Interventricular septum, mm −0.035 −0.21 to 0.14 0.70 0.013 −0.11 to 0.13 0.83
Posterior wall, mm 0.055 −0.10 to 0.21 0.49 −0.057 −0.16 to 0.046 0.28
Relative wall thickness −0.005 −0.013 to 0.004 0.27 −0.005 −0.01 to 0.0006 0.09
LV mass index, g/m2 3.28 0.83 to 5.73 0.009 1.06 −0.56 to 2.68 0.20
LV diastolic function
Transmitral E wave, cm/s −0.28 −2.18 to 1.62 0.77 −0.057 −1.30 to 1.19 0.93
Transmitral A wave, cm/s −0.42 −1.99 to 1.15 0.60 0.58 −0.46 to 1.61 0.28
Transmitral E/A ratio 0.034 −0.005 to 0.073 0.091 0.0012 −0.025 to 0.027 0.92
IVRT, ms −1.90 −3.81 to 0.012 0.052 1.61 0.36 to 2.86 0.011
Deceleration time, ms 2.20 −2.43 to 6.83 0.35 −0.70 −3.76 to 2.36 0.65
e′, cm/s −0.060 −0.33 to 0.21 0.66 0.20 0.022 to 0.37 0.027
E/e′ ratio 0.16 −0.061 to 0.38 0.16 −0.027 −0.17 to 0.12 0.71
Estimates are effect sizes associated with a doubling of hs-cTnT and NT-proBNP. hs-cTnT indicates hs-cardiac troponin T; NT-proBNP, amino terminal-pro-BNP; LV, left ventricle; LVEDV,
left ventricular end‐diastolic volume; IVRT, isovolumic relaxation time. Echocardiographic traits were adjusted for sex, age, bodymass index (not applicable to left atrial volume index, LV
mass index and LVEDV index), systolic blood pressure, heart rate, serum creatinine, previous history of cardiac disorders and antihypertensive drug treatment.
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TIMP-1 (P b 0.0001, Fig. 2D).
3.5. Sensitivity analysis
In sensitivity analyses, we included subjects with available data for
both NT-proBNP and hs-cTnT and we excluded 31 subjects with cardiac
valve disorders and 25 subjects with myocardial infarction and/or revas-
cularization. As shown in Supplemental Table S3, the results of these sensi-
tivity analyses, adjusted for covariables, were confirmatory for the
associations of hs-cTnT with LAVI and for the associations of NT-proBNP
with LV internal diastolic diameter, LVEDV index, IVRT and TDI e′mitral
annulus velocity. Moreover, by excluding subjects with cardiac disorders,
multivariable regression analysis confirmed that hs-cTnT was associated
with CITP (P b 0.0001) and TIMP-1 (P = 0.040) and that NT-proBNP
was associated with CITP (P b 0.0001) and TIMP-1 (P b 0.0001).
4. Discussion
The novelty of our study lies in the fact that we are reporting associ-
ations between the presence of subclinical cardiac remodelling, includ-
ing alterations in LA and LV morphology and function, with alterations
in circulating biomarkers of myocardial injury and hemodynamic stress
in subjects from a general population. In addition,we prove incremental
diagnostic value of the combination of hs-cTnT and NT-proBNP over the
classical risk factors as confirmed by 2 measures of improvement in
discrimination: IDI and continuous NRI. Furthermore, we first describe
that increments in the considered biomarkers of cardiomyocyte injury
associate with activation of mechanisms related to altered collagenme-
tabolism in the general population. In particular, we have reported that,
with adjustments applied: 1) circulating hs-cTnT was associated with a
higher risk of LAE, LVH, and LVDD; 2) in combination with NT-proBNP,
hs-cTnT improved the discrimination between subjects with and with-
out LAE, LVH and LVDD in the general population, as demonstrated by
the IDI and the continuous NRI; and 3) both hs-cTnT and NT-proBNP
were independently associated with circulating biomarkers of collagen
type I turnover, CITP and TIMP-1.
Our findings are in line with two recently published community-
based studies which explored in continuous and categorical analyses
the association between circulating hs-cTnT, alone or in combination
with NT-proBNP, and LV structure and function [4,9,20,21]. Although
in the Dallas Heart Study [4,9,20], hs-cTnT was only detected in 25%
(n = 957) of the study cohort, LVMI measured by magnetic resonanceimaging was associated with increased hs-cTnT level in multivariable-
adjusted analysis including only subjectswith detectable hs-cTnT levels.
In community-dwelling elderly subjects (mean age, 73 years old), Mas-
son et al. [21] found that hs-cTnT was significantly higher in subjects
with LVH or LVDD. Nadir et al. [22] recruited 300 asymptomatic individ-
uals with at least one cardiovascular risk factor and already receiving
primary prevention therapy. In unadjusted analysis, the authors dem-
onstrated that circulating hs-cTnT was associated with a higher preva-
lence of cardiac target organ damage such as LAE, LVH and LVDD [22].
In our study with adjustments applied, we demonstrated in continuous
and categorical analyses that circulating hs-cTnT is associatedwith both
LA and LV morphological alterations, as well as with LVDD, as assessed
from conventional echocardiographic measurements in a random sam-
ple of a general population. We confirmed that NT-proBNP is signifi-
cantly increased in subjects with LVDD [8]. Of notice, we performed
sensitivity analysis discarding participants with previous history of car-
diac diseasewhichprovided confirmatory results, particularly regarding
hs-cTnT associationwith LAVI andNT-proBNP associationwith LVDD. In
this regard,we believe that special attention should be given to the eval-
uation of the potential utility of circulating hs-cTnT as amarker of LA ab-
normalities in further community-based studies.
We also demonstrated that the combination of hs-cTnT with NT-
proBNP significantly increased the model's diagnostic utility for LAE,
LVH and LVDD as compared to amodel including only conventional car-
diovascular risk factors, as quantified by the IDI and the continuous NRI
analyses. LAE, LVH and LVDD, signs of cardiac remodelling and dysfunc-
tion, are strongly intercorrelated [23]. Each of these dichotomous traits
is independently associated with increased morbidity and mortality,
risk of HF and cardiovascular death [24–26]. In particular, a meta-
analysis combining 20 prospective studies shows that the adjusted
risk of future cardiovascular morbidity associated with baseline LVH
ranged from 1.5 to 3.5, with a weighted risk ratio of 2.3 for all studies
combined [27]. In addition, results obtained in a large clinical cohort in-
cluding patients with preserved EF [28] demonstrate that LAE significant-
ly predicts mortality risk, and adds to the overall mortality prediction in
these patients, independently of LV geometry. Moreover, the Olmsted
study [25] demonstrated that any degree of LVDD predicted all-cause
mortality, while controlling for age, sex and EF. Therefore, the validation
of effective screening tools for the identification with subclinical cardiac
remodelling is a major clinical need. The use of a single biomarker, for in-
stance BNP, for screening and early detection of LVH or LV systolic dys-
function in a general population has been found suboptimal [29]. Only
few community-based studies [9,30] investigated usefulness of a
Fig. 1. Prevalence of left atrial enlargement, left ventricular hypertrophy and left ventricular diastolic dysfunction in the population. Bars show the prevalence of left atrial enlargement, left
ventricular hypertrophy and left ventricular diastolic dysfunction in all the participants categorized according to levels of hs-cardiac troponin T (hs-cTnT) below the limit of blank (LoB=
3 ng/l) and to hs-cTnT quartiles (Panels A, B and C), and according to quartiles of amino terminal-pro‐BNP (NT-proBNP) (Panels D, E and F).
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with biomarkers of cardiac stress, such as NT-proBNP or BNP. In 2460 Fra-
mingham Study participants [30], the continuous NRI for the detection of
LVH and LV systolic dysfunction obtained by considering four cardiac
stress biomarkers such as soluble ST-2, growth differentiation factor-15
and high-sensitivity troponin I and BNP, in addition to the classical risk
factors, was only 21.2% (P b 0.0001). In our study, NRI for the addition
of two biomarkers of cardiac injury and stress, such as hs-cTnT and NT-
proBNP, was about 30% for all dichotomized cardiac traits (LAE, LVH
and LVDD). Thus, our study was the first to analyse the potentialdiagnostic utility of hs-cTnT and NT-proBNP to identify LAE, LVH and
LVDD as assessed by conventional echocardiographic technique in the
general population.
In our study, independently of other covariables, higher levels of hs-
cTnT and NT-proBNP were significantly associated with increments in
two collagen type I degradation markers, CITP and TIMP-1. Along
these lines, Kop et al. [10] followed up 353 elderly patients with symp-
tomatic HF (mean age 74 years old) for 3 years. The authors found that
increases in hs-cTnT were significantly associated with markers of al-
tered collagen metabolism, specifically, CITP and PIIINP [10]. Moreover,
Table 4
Association between cardiac remodelling and diastolic dysfunction and biomarkers (hs-cTnT
and NT-proBNP).
Biomarker/characteristic Odds ratio 95% CI P
hs-cTnT (n = 727)
Left atrial enlargement 1.86 1.22 to 2.83 0.004
LV hypertrophy 1.98 1.26 to 3.11 0.003
LV diastolic dysfunction 1.56 1.04 to 2.33 0.031
NT-proBNP (n = 694)
Left atrial enlargement 1.35 0.99 to 1.84 0.059
LV hypertrophy 1.12 0.81 to 1.54 0.50
LV diastolic dysfunction 1.44 1.10 to 1.89 0.009
Odds ratios are expressed for a doubling hs-cTnT and NT-proBNP. hs-cTnT indicates hs-
cardiac troponin T; NT-proBNP, amino terminal-pro-BNP; CI, confidence interval; LV, left
ventricle. Odds ratios were adjusted for sex, age, body mass index (not applicable to left
atrial enlargement and LV hypertrophy), systolic blood pressure, heart rate, serum creati-
nine, previous history of cardiac disorders and antihypertensive drug treatment.
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proBNP showed better survival (hazards ratio 0.12; P b 0.001) com-
pared with patients characterized by high levels of both biomarkers
[31].
It is known that biological processes activated in conditions of wall
stress and involved in tissue repair, not only require increased collagen
production but also result in altered collagen degradation, which may
contribute to alterations in themyocardial collagen network and subse-
quent cardiac remodelling [12,32,33]. Our study also showed for the
first time in the general population that increments in biomarkers of
cardiomyocyte injury and hemodynamic stress were positively associ-
ated with TIMP-1, which would result in a reduction in collagen degra-
dation. These results seem to be at odds with our finding of increased
collagen degradation, as indicated by increased CITP, in subjectswith el-
evated circulating hs-cTnT and NT-proBNP. However, the same inter-
play between TIMP-1 and CITP has been identified in patients with
untreated hypertension [32], which raises the hypothesis that increased
TIMP-1 may be a mechanism that, although not sufficient to trigger the
increment in collagen synthesis, may be counteracting or modulating
collagen degradation and, thus, contributing to the development of fi-
brosis in asymptomatic patients [32]. Contrary to our expectations, we
have not found significant associations between the aforementioned
collagen degradation markers and LV and LA echocardiographic abnor-
malities, although in both cases positive tendencies of association with
LVDD were found (P b 0.2, Supplemental Table S4). In this regard, it is
necessary to point out that, although several studies in amore patholog-
ical context have demonstrated that markers of collagen metabolism
are, at least in part, of cardiac origin [12], we cannot discard differentTable 5
Integrated discrimination improvement (IDI) and net reclassification improvement (NRI) for le
with addition of hs-cTnT or/and NT-proBNP to the logistic model.
Biomarker/characteristic Integrated discrimination improvement
IDI (%) 95% CI
hs-cTnT (n = 727)
Left atrial enlargement 1.25 0.09 to 2.41
LV hypertrophy 1.91 0.56 to 3.25
LV diastolic dysfunction 0.91 0.08 to 1.73
NT-ProBNP (n = 694)
Left atrial enlargement 0.84 0.0 to 1.69
LV hypertrophy 0.10 −0.17 to 0.38
LV diastolic dysfunction 0.73 0.04 to 1.43
hs-cTnT and NT-ProBNP (n = 694)
Left atrial enlargement 1.57 0.34 to 2.80
LV hypertrophy 1.72 0.35 to 3.08
LV diastolic dysfunction 1.92 0.69 to 3.14
The integrated discrimination improvement (IDI) is the difference between the discrimination
The discrimination slope is the difference in predicted probabilities (%) between subjects with
reclassification improvement (NRI) reflects the improvement in discriminative power by addin
(see Table 3). hs-cTnT indicates hs-cardiac troponin T; NT-proBNP, amino terminal-pro-BNP; Lsources for early alterations in the content of collagen biomarkers in
the blood from subjects belonging to the general population. Therefore,
several confounding factors may be influencing the association of these
collagen biomarkers with echocardiographic abnormalities in this con-
text. Thus, we believe that associations of biomarkers of collagen type
I degradation with echocardiographic parameters of cardiac remodel-
ling in the general population need to be further studied in larger and
multi-ethnic community studies. On the other hand, in contrast to the
studies performed in patients with HF [10,34], we do not observe asso-
ciations of hs-cTnT or NT-proBNP with PIIINP. Alterations in PIIINP may
reflect a shift from type I to type III collagen synthesis over time in the
transition from cardiac remodelling to HF [10] and, therefore, its con-
centration may not be that unbalanced in the general population.
4.1. Study limitations
The present study must be interpreted within the context of its
limitation. First, the cross-sectional design of the study does not allow
for a causal interpretation of the relationships found. Second, variables
reflecting LA and LV structure and function are quantitative traits
prone to measurement error. However, only one experienced observer
performed all echocardiographic examinations. Third, it must be recog-
nized that inclusion of untreated subjects and participants treated with
different classes of antihypertensive drugs might influence our findings
and their interpretation. However, the pharmacological treatment did
not seem to affect the associations found in this study. Fourth, we are
aware of the limitations of interpreting IDI and NRI within the clinical
context and the risk of overestimating the information provided by
both indexes [35].
4.2. Summary
In summary, in our population-based study, the combination of hs-
cTnT and NT-proBNP demonstrated incremental diagnostic utility over
clinical risk factors to detect LA and LV remodelling and dysfunction.
Moreover, we have found that hs-cTnT and NT-proBNP increments
may indicate alterations in myocardial collagen metabolism. Therefore,
we believe thatwe are significantly expanding the information available
on the potential diagnostic capacity of the combination of hs-cTnT and
NT-proBNP, not only for the detection of LV structural and functional re-
modelling, but also to identify subclinical LA morphological abnormali-
ties. Furthermore, we add new pathophysiological meaning, since we
are reporting associations among collagen-related mechanisms and
the cardiomyocyte injury and hemodynamic stress-related processes
leading to myocardial remodelling in the general population. Thus, ourft atrial enlargement, left ventricular hypertrophy and left ventricular diastolic dysfunction
Net reclassification improvement
P NRI (%) 95% CI P
0.035 20.5 0.77 to 40.2 0.042
0.006 38.6 16.1 to 61.1 0.001
0.031 5.26 −11.4 to 21.9 0.54
0.050 27.4 7.34 to 47.4 0.009
0.46 6.48 −30.2 to 17.2 0.59
0.039 27.3 10.5 to 44.0 0.002
0.012 27.7 7.49 to 48.0 0.008
0.014 32.8 8.63 to 54.9 0.009
0.002 29.3 12.8 to 45.8 0.0007
slopes of basic models (see Table 3) and basic models extended with a predictor variable.
and without left atrial enlargement, LV hypertrophy or LV diastolic dysfunction. The net
g hs-cTnT and/or NT-proBNP to a logistic model already including important covariables
V, left ventricular.
Fig. 2. Associations between biomarkers of cardiac injury/stress and collagen type I turnover. Symbols represent geometric means and 95 confidence intervals of CITP and TIMP-1 levels
adjusted for age, sex, bodymass index, systolic blood pressure, serum creatinine, previous history of cardiac disorders and antihypertensive drug treatment. Panels present the association
of CITP and TIMP-1 in subjects with hs-cTnT levels below the limit of blank (LoB=3 ng/l) and in hs-cTnT quartiles (total number of participants=727) (Panels A and B, respectively), and
inNT-proBNP quartiles (total number of participants=694) (Panels C andD, respectively). *P b 0.05 vs hs-cTnT below the LoB and the rest of hs-cTnT quartiles; ‡P b 0.05 vs hs-cTnT below
the LoB; †P b 0.05 vs first NT-proBNP quartile.
184 S. Ravassa et al. / International Journal of Cardiology 185 (2015) 177–185results may contribute to the search for pre-screening diagnostic tools in
subjects with suspected subclinical LV and LA alterations. In this regard,
additional studies of larger multi-ethnic cohorts are needed to confirm
our results and further prospective studies are required to determine
whether the combined use of biomarkers of cardiomyocyte injury/stress
and collagenmetabolism is useful for patient risk stratification and thera-
py guidance in at risk populations.
Sources of funding
Thisworkwas supported by the EuropeanUnion (grants IC15-CT98-
0329-EPOGH, LSHM-CT-2006-037093-InGenious HyperCare, HEALTH-
F4-2007-201550-HyperGenes, HEALTH-2011-278249-EU-MASCARA,
HEALTH-F7-305507-HoMAGE), and ERC Advanced Grant-2011-
294713-EPLORE supported the Studies Coordinating Centre (Leuven,
Belgium). The Studies Coordinating Centre also received grants from the
Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the
Flemish Community, Brussels, Belgium (grants G.0734.09, G.0880.13and G. 0881.13). The work performed in the Centre for Applied Medical
Research, University of Navarra (Pamplona, Spain) was supported by
the European Union (grants FP7-HEALTH-2011-278249-EU-MASCARA
and HEALTH-F7-305507-HoMAGE) and by the Ministry of Economy and
Competitiveness (Instituto de Salud Carlos III, grant RD12/0042/0009).Conflict of interest
None.Acknowledgments
The authors gratefully acknowledge the expert assistance of Linda
Custers, Marie-Jeanne Jehoul, Daisy Thijs and Hanne Truyens (Leuven,
Belgium) and the valuable technical assistance of Sonia Martínez and
Ana Igea (Pamplona, Spain).
185S. Ravassa et al. / International Journal of Cardiology 185 (2015) 177–185Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ijcard.2015.03.046.
References
[1] T. Kuznetsova, L. Herbots, Y. Jin, K. Stolarz-Skrzypek, J.A. Staessen, Systolic and dia-
stolic left ventricular dysfunction: from risk factors to overt heart failure, Expert.
Rev. Cardiovasc. Ther. 8 (2010) 251–258.
[2] R.D. Kociol, P.S. Pang, M. Gheorghiade, G.C. Fonarow, C.M. O'Connor, G.M. Felker,
Troponin elevation in heart failure prevalence, mechanisms, and clinical implica-
tions, J. Am. Coll. Cardiol. 56 (2010) 1071–1078.
[3] H.D. White, Pathobiology of troponin elevations: do elevations occur with myocar-
dial ischemia as well as necrosis? J. Am. Coll. Cardiol. 57 (2011) 2406–2408.
[4] J.A. de Lemos, M.H. Drazner, T. Omland, C.R. Ayers, A. Khera, A. Rohatgi, I. Hashim,
J.D. Berry, S.R. Das, D.A. Morrow, D.K. McGuire, Association of troponin T detected
with a highly sensitive assay and cardiac structure and mortality risk in the general
population, JAMA 304 (2010) 2503–2512.
[5] K.M. Eggers, L. Lind, H. Ahlström, T. Bjerner, C. Ebeling Barbier, A. Larsson, P. Venge,
B. Lindahl, Prevalence and pathophysiological mechanisms of elevated cardiac tro-
ponin I levels in a population-based sample of elderly subjects, Eur. Heart J. 29
(2008) 2252–2258.
[6] J.T. Saunders, V. Nambi, J.A. de Lemos, L.E. Chambless, S.S. Virani, E. Boerwinkle, R.C.
Hoogeveen, X. Liu, B.C. Astor, T.H. Mosley, A.R. Folsom, G. Heiss, J. Coresh, C.M.
Ballantyne, Cardiac troponin T measured by a highly sensitive assay predicts coro-
nary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Com-
munities Study, Circulation 123 (2011) 1367–1376.
[7] V.K. Munagala, J.C. Burnett Jr., M.M. Redfield, The natriuretic peptides in cardiovas-
cular medicine, Curr. Probl. Cardiol. 29 (2004) 707–769.
[8] T. Kuznetsova, L. Herbots, B. López, Y. Jin, T. Richart, L. Thijs, A. González, M.C.
Herregods, R.H. Fagard, J. Díez, J.A. Staessen, Prevalence of left ventricular diastolic
dysfunction in a general population, Circ. Heart Fail. 2 (2009) 105–112.
[9] I.J. Neeland, M.H. Drazner, J.D. Berry, C.R. Ayers, C. deFilippi, S.L. Seliger, V. Nambi,
D.K. McGuire, T. Omland, J.A. de Lemos, Biomarkers of chronic cardiac injury and he-
modynamic stress identify a malignant phenotype of left ventricular hypertrophy in
the general population, J. Am. Coll. Cardiol. 61 (2013) 187–195.
[10] W.J. Kop, J.S. Gottdiener, C.R. deFilippi, E. Barasch, S.L. Seliger, N.S. Jenny, R.H.
Christenson, Cardiacmicroinjurymeasuredby troponinTpredicts collagenmetabolism
in adults agedN=65 years with heart failure, Circ. Heart Fail. 5 (2012) 406–413.
[11] K.T. Weber, C.G. Brilla, Pathological hypertrophy and cardiac interstitium. Fibrosis
and renin–angiotensin–aldosterone system, Circulation 83 (1991) 1849–1865.
[12] B. López, A. González, J. Díez, Circulating biomarkers of collagen metabolism in car-
diac diseases, Circulation 121 (2010) 1645–1654.
[13] J.S. Gottdiener, J. Bednarz, R. Devereux, J. Gardin, A. Klein, W.J. Manning, A.
Morehead, D. Kitzman, J. Oh, M. Quinones, N.B. Schiller, J.H. Stein, N.J. Weissman,
American Society of Echocardiography, American Society of Echocardiography rec-
ommendations for use of echocardiography in clinical trials, J. Am. Soc.
Echocardiogr. 17 (2004) 1086–1119.
[14] E. Agabiti-Rosei, M.L. Muiesan, Hypertensive left ventricular hypertrophy: patho-
physiological and clinical issues, Blood Press. 10 (2001) 288–298.
[15] R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, P.A. Pellikka, M.H.
Picard, M.J. Roman, J. Seward, J.S. Shanewise, S.D. Solomon, K.T. Spencer, M.S.
Sutton, W.J. Stewart, A report from the American Society of Echocardiography's
Guidelines and Standards Committee and the Chamber Quantification Writing
Group, developed in conjunction with the European Association of Echocardiogra-
phy, a branch of the European Society of Cardiology, J. Am. Soc. Echocardiogr. 18
(2005) 1440–1463.
[16] M. Kloch-Badelek, T. Kuznetsova, W. Sakiewicz, V. Tikhonoff, A. Ryabikov, A.
González, B. López, L. Thijs, Y. Jin, S. Malyutina, K. Stolarz-Skrzypek, E. Casiglia, J.
Díez, K. Narkiewicz, K. Kawecka-Jaszcz, J.A. Staessen, European Project On Genes
in Hypertension (EPOGH) Investigators, Prevalence of left ventricular diastolic dys-
function in European populations based on cross-validated diagnostic thresholds,
Cardiovasc. Ultrasound 10 (2012) 10.[17] T. Kuznetsova, L. Thijs, J. Knez, L. Herbots, Z. Zhang, J.A. Staessen, Prognostic value of
left ventricular diastolic dysfunction in a general population, J. Am. Heart Assoc. 3
(2014) e000789.
[18] T. Kuznetsova, V. Codd, S. Brouilette, L. Thijs, A. González, Y. Jin, T. Richart, P. van der
Harst, J. Díez, J.A. Staessen, N.J. Samani, Association between left ventricular mass
and telomere length in a population study, Am. J. Epidemiol. 172 (2010) 440–450.
[19] M.J. Pencina, R.B. D'Agostino Sr., E.W. Steyerberg, Extensions of net reclassification
improvement calculations to measure usefulness of new biomarkers, Stat. Med. 30
(2011) 11–21.
[20] M.G. Khouri, R.M. Peshock, C.R. Ayers, J.A. de Lemos, M.H. Drazner, A 4-tiered classi-
fication of left ventricular hypertrophy based on left ventricular geometry: the Dal-
las Heart Study, Circ. Cardiovasc. Imaging 3 (2010) 164–171.
[21] S. Masson, R. Latini, G.F. Mureddu, N. Agabiti, M. Miceli, G. Cesaroni, F. Forastiere,
U.H. Wienhues-Thelen, D. Block, C. Zaugg, T. Vago, A. Boccanelli, PREDICTOR study,
High-sensitivity cardiac troponin T for detection of subtle abnormalities of cardiac
phenotype in a general population of elderly individuals, J. Intern. Med. 273
(2013) 306–317.
[22] M.A. Nadir, S. Rekhraj, L. Wei, T.K. Lim, J. Davidson, T.M. MacDonald, C.C. Lang, E.
Dow, A.D. Struthers, Improving the primary prevention of cardiovascular events
by using biomarkers to identify individuals with silent heart disease, J. Am. Coll.
Cardiol. 60 (2012) 960–968.
[23] C. Cuspidi, F. Negri, C. Sala, C. Valerio, G. Mancia, Association of left atrial enlarge-
ment with left ventricular hypertrophy and diastolic dysfunction: a tissue Doppler
study in echocardiographic practice, Blood Press. 21 (2012) 24–30.
[24] T.S. Tsang,M.E. Barnes, B.J. Gersh, Y. Takemoto, A.G. Rosales, K.R. Bailey, J.B. Seward, Pre-
diction of risk for first age-related cardiovascular events in an elderly population: the
incremental value of echocardiography, J. Am. Coll. Cardiol. 42 (2003) 1199–1205.
[25] M.M. Redfield, S.J. Jacobsen, J.C. Burnett Jr., D.W. Mahoney, K.R. Bailey, R.J.
Rodeheffer, Burden of systolic and diastolic ventricular dysfunction in the commu-
nity: appreciating the scope of the heart failure epidemic, JAMA 289 (2003)
194–202.
[26] S. Gupta, S.A. Matulevicius, C.R. Ayers, J.D. Berry, P.C. Patel, D.W. Markham, B.D.
Levine, K.M. Chin, J.A. de Lemos, R.M. Peshock, M.H. Drazner, Left atrial structure
and function and clinical outcomes in the general population, Eur. Heart J. 34
(2013) 278–285.
[27] B.A. Vakili, P.M. Okin, R.B. Devereux, Prognostic implications of left ventricular hy-
pertrophy, Am. Heart J. 141 (2001) 334–341.
[28] D.A. Patel, C.J. Lavie, R.V. Milani, H.O. Ventura, Left atrial volume index predictive of
mortality independent of left ventricular geometry in a large clinical cohort with
preserved ejection fraction, Mayo Clin. Proc. 86 (2011) 730–737.
[29] R.S. Vasan, E.J. Benjamin, M.G. Larson, E.P. Leip, T.J. Wang, P.W.Wilson, D. Levy, Plasma
natriuretic peptides for community screening for left ventricular hypertrophy and sys-
tolic dysfunction: the Framingham heart study, JAMA 288 (2002) 1252–1259.
[30] V. Xanthakis, M.G. Larson, K.C. Wollert, J. Aragam, S. Cheng, J. Ho, E. Coglianese, D.
Levy, W.S. Colucci, G. Michael Felker, E.J. Benjamin, J.L. Januzzi, T.J. Wang, R.S.
Vasan, Association of novel biomarkers of cardiovascular stress with left ventricular
hypertrophy and dysfunction: implications for screening, J. Am. Heart Assoc. 2
(2013) e000399.
[31] D.N. Tziakas, G.K. Chalikias, D. Stakos, S.V. Chatzikyriakou, D. Papazoglou, K. Mitrousi, A.
Lantzouraki, A. Thomaidi, H. Boudoulas, S. Konstantinides, Independent and additive
prognostic ability of serumcarboxy-terminal telopeptide of collagen type-I in heart fail-
ure patients: a multi-marker approach with high-negative predictive value to rule out
long-term adverse events, Eur. J. Prev. Cardiol. 19 (2012) 62–71.
[32] M.M. Lindsay, P. Maxwell, F.G. Dunn, TIMP-1: a marker of left ventricular diastolic
dysfunction and fibrosis in hypertension, Hypertension 40 (2002) 136–141.
[33] A. González, B. López, R. Querejeta, E. Zubillaga, T. Echeverría, J. Díez, Filling pres-
sures and collagen metabolism in hypertensive patients with heart failure and nor-
mal ejection fraction, Hypertension 55 (2010) 1418–1424.
[34] S. de Denus, J. Lavoie, A. Ducharme, E. O'Meara, N. Racine, M.G. Sirois, P.E. Neagoe, L.
Zhu, J.L. Rouleau, M. White, Differences in biomarkers in patients with heart failure
with a reduced vs a preserved left ventricular ejection fraction, Can. J. Cardiol. 28
(2012) 62–68.
[35] N.R. Cook, Clinically relevant measures of fit? A note of caution, Am. J. Epidemiol.
176 (2012) 488–491.
1 
 
 
 
SUPPLEMENTAL 
MATERIAL 
2 
 
 
Biomarkers of cardiomyocyte injury and stress identify left atrial 
and left ventricular remodelling and dysfunction: a population-
based study  
Ravassa, Biomarkers and cardiac remodelling 
Susana Ravassa1*, Tatiana Kuznetsova2*, Nerea Varo3,  
Lutgarde Thijs2, Christian Delles4, Anna Dominiczak4,   
Javier Díez1,5 and Jan A. Staessen2,6  
*Both authors contributed equally to this work 
1Division of Cardiovascular Sciences, Centre for Applied Medical Research, University of 
Navarra, Pamplona, Spain; 2 the Studies Coordinating Centre, Research Unit of  Hypertension 
and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, 
University of Leuven, Belgium; 3Department of Biochemistry, University of Navarra Clinic, 
University of Navarra, Pamplona Spain; 4Institute of Cardiovascular and Medical Sciences, 
University of Glasgow, Scotland, UK; 5Department of Cardiology and Cardiac Surgery, 
University of Navarra Clinic, University of Navarra, Pamplona, Spain. 6Department of 
Epidemiology, University of Maastricht, Maastricht, The Netherlands.  
  
3 
 
Supplemental Methods 
Study Participants  
The Ethics Committee of the University of Leuven approved the Flemish Study on Environment, 
Genes and Health Outcomes (FLEMENGHO).  From August 1985 until December 2005, we 
identified a random population sample stratified by sex and age from a geographically defined 
area in northern Belgium [1]. Households, defined as those who lived at the same address, were 
the sampling unit. We numbered households consecutively, and generated a random-number list 
by use of a SAS random function. Households with a number matching the list were invited. The 
initial participation rate was 78.0%. 
 The participants were repeatedly followed up.  From May 2005 until May 2010, we 
invited 1208 former participants for a follow-up examination at the field centre, including 
echocardiography.  However, 153 former participants were unavailable for follow-up, because 
they had died (n=26), because they had been institutionalised or were too ill (n=27), or because 
they had moved out of the area (n=100).  Of the remaining 1055 former participants, 828 
renewed their informed consent. The participation rate for the follow-up examination was 
therefore 78.5%. We excluded 15 subjects, because of atrial fibrillation (n=8) or the presence of 
an artificial pacemaker (n=3), or because diastolic function could not be reliably determined 
(n=4).  We discarded further subjects (n=86) from analysis because serum samples were not 
available (n=44) or amount of serum was insufficient (n=42) for hs-cTnT measurements.  
Therefore, the number of participants statistically analyzed totaled 727.  
Echocardiography   
The participants refrained from smoking, heavy exercise, and drinking alcohol or caffeine-
containing beverages for at least 3 hours before echocardiography.  The blood pressure during 
echocardiography was the average of two readings, obtained with a validated OMRON 705IT 
device (Omron Corp., Tokyo, Japan) at the end of the echocardiographic examination.  
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Data Acquisition  
One experienced physician (T.K.) did the ultrasound examination [2], using a Vivid7 Pro (GE 
Vingmed, Horten, Norway) interfaced with a 2.5- to 3.5-MHz  phased-array probe, according to 
the recommendations of the American Society of Echocardiography [3].  With the subjects in 
partial left decubitus and breathing normally, the observer obtained images, together with a 
simultaneous ECG signal, along the parasternal long and short axes and from the apical 4- and 
2-chamber long-axis views.  All recordings included at least 5 cardiac cycles and were digitally 
stored for off-line analysis.  M-mode echocardiograms of the LV were recorded from the 
parasternal long-axis view under control of the two-dimensional image.  The ultrasound beam 
was positioned just below the mitral valve at the level of the posterior chordae tendineae. To 
record pulsed wave Doppler mitral and pulmonary vein (PV) flow velocities from the apical 
window and the isovolumetric relaxation time (IVRT), the observer positioned the Doppler 
sample volume at the mitral valve tips, in the right superior PV, and between the LV outflow and 
mitral inflow, respectively.  
Using TDI (Tissue Doppler Imaging), the observer recorded low-velocity, high-intensity 
myocardial signals at a high frame rate (>190 FPS), while adjusting the imaging angle to ensure 
a parallel alignment of the ultrasound beam with the myocardial segment of interest.  From the 
apical window, the sonographer placed a 5-mm Doppler sample at the septal, lateral, inferior and 
posterior sites of the mitral annulus.   
Off-Line Analysis  
One experienced physician (T.K.) analyzed digitally stored images, averaging 3 heart cycles for 
statistical analysis, using a workstation running the EchoPac, version 4.0.4 software package (GE 
Vingmed, Horten, Norway).  The LV internal diameter and interventricular septal and posterior 
wall thickness were measured at end-diastole from the 2-dimensionally guided M-mode tracing. 
When optimal orientation of M-mode ultrasound beam could not be obtained, the reader 
performed linear measurements on correctly oriented two-dimensional images.  End-diastolic LV 
dimensions were used to calculate LV mass by an anatomically validated formula. Relative wall 
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thickness (RWT) was calculated as the ratio of (interventricular septum + posterior wall)/LV 
internal diameter at end-diastole. LV mass index (LVMI) was LV mass divided by body surface 
area (BSA), calculated as body weight
0.425
 (in kg) x body height
0.725
 (in cm) x 0.007184. LV 
hypertrophy (LVH) was a LV mass index exceeding 110 g/m
2
 in women, and 125 g/m
2
 in men 
[4]. We calculated LV ejection fraction (EF) from LV end-systolic and end-diastolic volumes 
(LVESV and LVEDV, respectively) measured from the apical 4- and 2-chambers views, using 
the standard Simpson’s method. LVESV and LVEDV were indexed by BSA (LVEDVi and 
LVESVi, respectively). We measured left atrial (LA) dimensions in 3 orthogonal planes: the 
parasternal long, lateral, and supero-inferior axes.  LA volume was calculated using the prolate-
elipsoid method and was indexed to BSA. LA enlargement (LAE) was a left atrial volume index 
(LAVI) exceeding 29 ml/m
2
 [5]. 
Reproducibility  
To determine intra-observer reproducibility, the experienced echocardiographists (T.K.) 
analyzed the echocardiograms of 17 subjects twice.  Intra-observer reproducibility coefficient of 
a measurement was the 2SD interval about the mean of the relative differences across pairwise 
readings. The intra-observer reproducibility was 2.2% for LV internal end-diastolic diameter, 
4.6% for LV wall thickness, 4.3% for LV mass.
7
 For tissue Doppler velocities, as reported 
previously [2], the reproducibility across the four sampling sites ranged from 4.48% to 5.34% for 
e’ velocities and from 3.96% to 4.52% for a’ velocities.  
Other Measurements  
We used a validated questionnaire to inquire about life-style, medical history, use of 
medications, as well as smoking and drinking habits. The conventional blood pressure was the 
average of five consecutive auscultatory readings obtained with the subject in the seated position.  
Hypertension was defined as a blood pressure of at least 140 mm Hg systolic or 90 mm Hg 
diastolic or as the use of antihypertensive drugs. Body mass index was weight in kilograms 
divided by the square of height in meters.  
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Biochemical Measurements  
On the day of the echocardiographic examination, after the subjects had rested in the supine 
position for at least 45 min, venous blood samples were collected into serum and EDTA tubes. 
After centrifuging, the plasma and serum were separated, aliquoted and stored at  
-80°C.  
 hs-cTnT levels were measured in serum using a highly sensitive assay (Troponin T hs 
STAT, Roche Diagnostics) optimized on the Cobas 8000 modular analyser series (Roche 
Diagnostics). The limit of blank of the assay has been established in 3 ng of cTnT/l and the inter-
assay coefficient was 4.6%. The presence of the analyte was considered in all samples with 
values above 3 ng/l hs-cTnT. The upper reference limit (99
th
 percentile) provided by the 
manufacturer for hs-cTnT was 14 ng/l, 95% confidence interval (12.7 to 24.9 ng/l).  
 PICP was quantified in serum by sandwich enzyme linked immunosorbent assay (ELISA) 
using the METRA EIA kit (Quidel Corporation, San Diego, CA). The inter-assay and intra-assay 
variations for determining PICP were 6.4% and 4.5 %, respectively. The lower limit of detection 
was 0.2 g of PICP/l. Serum CITP was determined by a quantitative enzyme immunoassay 
(Orion Diagnostica, Espoo, Finland). The inter- and intra-assay variations for determining CITP 
were 13.1% and 10%, respectively. The lower detection limit was 0.30 g of CITP/l. Free TIMP-
1 was determined in serum by ELISA method (TIMP-1 Human Biotrak ELISA System from GE 
Healthcare, UK Limited). The interassay and intra-assay variations for determining TIMP-1 were 
12.8% and 2.6%, respectively. The lower detection limit was 1.25 ng of TIMP-1/ml.  PIIINP was 
assessed in serum as a marker of collagen type III turnover by ELISA (MyBioSource, San 
Diego, CA). Inter- and intra-assay coefficients were both < 15%. The limit of detection was 31.3 
pg of PIIINP/ml.  
 NT-proBNP was measured in plasma by a competitive enzyme immnunoassay (EIA) for 
research use (Biomedica Gruppe, Vienna, Austria) [6], as previously described [2]. The 
interassay and intra-assay variations were lower than 15%. The lower detection limit was 5 pmol 
of NT-proBNP/l. The standard range provided by the manufacturer of the EIA is from 0 to 1000 
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pmol/l (median, 208 pmol/L; 95% percentile, 300 pmol/L). From the considered 727 
participants, plasma samples from 33 subjects were not available and, therefore, NT-proBNP 
was measured in 694 plasma samples.  
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Table S1   Clinical characteristics of participants by NT-proBNP quartiles  
Characteristic  NT-proBNP quartiles 
P-value 
Low   
(n = 173) 
Medium-Low  
(n = 174) 
Medium-High  
(n = 175) 
High  
(n = 172) 
Limits, ng/l   <1204 1204–1743 1744–2494 >2494 … 
Anthropometrics       
Age, y  47.9  12.7 49.8 ± 14.9 53.0  15.5 55.9 ± 16.2 <.0001 
Body mass index, kg/m2  26.5 ± 4.1 25.9 ± 4.0 26.5 ± 4.4 26.5 ± 4.2 0.67 
Sex, women n (%) 72 (41.6) 83 (47.7) 93 (53.1) 107 (62.2) <.0001 
Systolic pressure, mm Hg   129.6 ± 16.0 126.6  16.4 129.2 ± 17.2 133.2  20.3 0.026 
Diastolic pressure, mm Hg  82.3 ± 9.2 78.3  8.8 79.1 ± 8.9 78.9  9.9 0.003 
Heart rate, beats/min  62.9 ± 10.1 60.5  9.2 59.4 ± 9.3 60.0  9.7 0.004 
Questionnaire data       
Current smoking, n (%)   39 (22.5) 32 (18.4) 45 (25.7) 36 (20.9) 0.86 
Drinking alcohol, n (%)   77 (44.5) 84 (48.3) 72 (41.1) 57 (33.1) 0.014 
Hypertensive, n (%)   70 (40.5) 59 (33.9) 73 (41.7) 85 (49.4) 0.039 
Treated for hypertension, n (%)   37 (21.4) 36 (20.7) 46 (26.3) 56 (32.6) 0.008 
History of cardiac disorders, n (%) 3 (1.7) 0 (0.0) 11 (6.3) 14 (8.2) <.0001 
Biochemical data      
Total cholesterol, mmol/l 5.26 ± 0.95 5.33 ± 0.97 5.31 ± 1.05 5.23 ± 0.95 0.71 
Glucose, mmol/l 4.96 ± 0.94 4.91 ± 0.55 5.01 ± 0.93 4.95 ± 0.80 0.83 
Serum creatinine, mmol/l 85.6 ± 13.3 84.1 ± 11.8 85.2 ± 13.8 84.8 ± 21.5 0.80 
 PICP, µg/l 88.3 (58.7 to 150) 90.8 (58.6 to 164) 88.3 (56.6 to 157) 88.6 (62.5 to 136) 0.67 
 CITP, µg/l 4.89 (3.30 to 7.19) 5.24 (3.35 to 8.15) 5.35 (3.27 to 8.14) 5.51 (3.26 to 8.44) 0.001 
 PIIINP, µg/l 509 (262 to 1333) 581 (260 to 1175) 542 (280 to 1319) 541 (224 to 1606) 0.92 
 TIMP-1, µg/l 593 (455 to 848) 629 (443 to 881) 671 (490 to 903) 677 (521 to 958) <.0001 
Values are mean (±SD), geometric mean (10% to 90% interval), or number of subjects (%). NT-proBNP indicates amino terminal-pro-BNP; PICP, carboxyterminal 
propeptide of procollagen type I; CITP, carboxyterminal telopeptide of type I collagen; PIIINP, aminoterminal propeptide of procollagen III; TIMP-1, tissue inhibitor of 
the matrix metalloproteinase type 1. P-values are for differences across quartiles.   
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Table S2   Echocardiographic characteristics of participants by NT-proBNP quartiles 
Characteristic  NT-proBNP quartiles 
P-value Low   
(n = 173) 
Medium-Low  
(n = 174) 
Medium-High  
(n = 175) 
High  
(n = 172) 
Limits, ng/l   <1204 1204–1743 1744–2494 >2494 … 
Conventional echocardiography       
Left atrial volume index, ml/m
2
  21.9 ± 5.2 22.2 ± 5.9 23.3 ± 6.8 24.2 ± 7.0 <.0001 
LV internal diastolic diameter, mm  50.0 ± 4.8 50.4 ± 4.4 50.4 ± 4.7 50.6 ± 5.3 0.28 
LVEDV index, ml/m
2
 52.6 ± 10.2 54.2 ± 12.0 54.4 ± 11.6 53.2 ± 11.1 0.61 
LVESV index, ml/m
2
 20.1 ± 4.9 20.3 ± 5.6 20.7 ± 5.3 20.5 ± 6.9 0.46 
Interventricular septum, mm  9.9 ± 1.5 9.6 ± 1.7 10.0 ± 1.7 9.9 ± 1.7 0.33 
Posterior wall, mm  9.1 ± 1.3 8.8 ± 1.5 9.0 ± 1.5 9.0 ± 1.5 0.70 
Relative wall thickness 0.38 ± 0.06 0.37  0.07 0.38 ± 0.07 0.38  0.07 0.91 
LV mass, g  172.6 ± 45.2 168.7  48.1 174.7 ± 48.9 176.0  52.9 0.34 
LV mass index, g/m
2
  91.8 ± 20.2 90.8  21.2 93.7 ± 21.7 96.2  24.7 0.03 
Ejection fraction, %  62.9 ± 6.3 63.5  6.6 62.7 ± 6.9 62.9  7.3 0.70 
Doppler echocardiography      
Transmitral E wave, cm/s 75.3 ± 14.5 77.4  16.1 75.0 ± 16.8 73.9  16.6 0.23 
Transmitral A wave, cm/s 62.4 ± 16.1 63.1  16.3 65.7 ± 18.4 70.3  18.6 <.0001 
Transmitral E/A ratio 1.30 ± 0.44 1.32 ± 0.50 1.23 ± 0.47 1.15 ± 0.48 0.001 
IVRT, ms 94.1 ± 13.7 99.6 ± 14.9 101.2 ± 15.3 101.8 ± 16.9 <.0001 
Deceleration time, ms 162.9 ± 33.8 166.2 ± 33.7 174.7 ± 40.8 169.1 ± 40.1 0.03 
e’, cm/s 11.7 ± 3.3 12.0 ± 3.7 11.1 ± 3.4 10.7 ± 3.9 0.002 
E/e’ ratio 6.8 ± 1.8 6.9 ± 1.9 7.2 ± 2.1 7.6 ± 2.7 <.0001 
Values are mean ± SD. NT-proBNP indicates amino terminal-pro-BNP;  LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
IVRT, isovolumic relaxation time. P-values are for differences across groups.
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Table S3   Adjusted echocardiographic traits in relation to hs-cTnT and NT-proBNP in subjects without cardiovascular 
diseases 
Characteristics Serum hs-cTnT (n=639)  Plasma NT-proBNP (n=639) 
 Estimate 95% CI P  Estimate 95% CI P 
Left atrial volume index, ml/m
2
 0.94 0.18 to 1.71 0.016  0.36 -0.12 to 0.84 0.14 
LV morphology        
LV internal diastolic diameter, mm 0.44 -0.16 to 1.04 0.15  0.48 0.10 to 0.86 0.012 
LVEDVindex, ml/m
2
 0.87 -0.65 to 2.39 0.26  1.11 0.19 to 2.03 0.019 
Interventricular septum, mm -0.07 -0.26 to 0.13 0.50  0.026 -0.096 to 0.15 0.67 
Posterior wall, mm 0.03 -0.14 to 0.20 0.72  -0.058 -0.17 to 0.049 0.29 
Relative wall thickness -0.004 -0.01 to 0.005 0.42  -0.004 -0.009 to 0.002 0.21 
LV mass index, g/m
2
 2.13 -0.39 to 4.64 0.09  0.71 -0.88 to 2.29 0.38 
LV diastolic function        
Transmitral E wave, cm/s  -0.76 -2.83 to 1.31 0.47  -0.63 -1.93 to 0.67 0.34 
Transmitral A wave, cm/s  -0.11 -1.75 to 1.52 0.89  0.62 -0.41 to 1.65 0.24 
Transmitral E/A ratio 0.02 -0.02 to 0.07 0.33  -0.005 -0.033 to 0.022 0.71 
   IVRT, ms -2.39 -4.42 to -0.36 0.021  1.74 0.46 to 3.01 0.008 
   Deceleration time, ms 1.15 -3.70 to 5.99 0.64  1.63 -1.42 to 4.68 0.29 
   e’, cm/s 0.06 -0.24 to 0.35 0.70  0.21 0.027 to 0.40 0.025 
   E/e’ ratio -0.01 -0.22 to 0.21 0.96  -0.11 -0.24 to 0.026 0.11 
Estimates are effect sizes associated with a doubling of hs-cTnT and NT-proBNP. hs-cTnT indicates hs-cardiac troponin T; NT-proBNP, amino terminal-pro-
BNP; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; IVRT, isovolumic relaxation time. Echocardiographic traits were adjusted for sex, age, 
body mass index (not applicable to left atrial volume index, LV mass index and LVEDV index), systolic blood pressure, heart rate, serum creatinine and 
antihypertensive drug treatment.  
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Table S4   Association between cardiac remodelling and diastolic dysfunction and 
biomarkers of collagen metabolism (CITP and TIMP-1)  
Biomarker/ Characteristic Odd Ratio 95% CI P 
CITP (n=727) 
   
Left atrial enlargement 1.00 0.63 to 1.58 0.99 
LV hypertrophy 1.19 0.73 to 1.96 0.48 
LV diastolic dysfunction 1.40 0.91 to 2.16 0.13 
TIMP-1 (n=727) 
   
Left atrial enlargement 0.71 0.34 to 1.45 0.35 
LV hypertrophy 1.18 0.55 to 2.55 0.67 
LV diastolic dysfunction 1.64 0.84 to 3.22 0.15 
 
Odds ratios are expressed for a doubling CITP and TIMP-1. CITP indicates carboxyterminal telopeptide of type I 
collagen; TIMP-1, tissue inhibitor of the matrix metalloproteinase type 1; CI, confidence interval; LV, left ventricle. Odd 
ratios were adjusted for sex, age, body mass index (not applicable to left atrial enlargement and LV hypertrophy), systolic 
blood pressure, heart rate, serum creatinine, previous history of cardiac disorders and antihypertensive drug treatment. 
